# Elfabrio (pegunigalsidase alfa) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pegunigalsidase-alfa

> Elfabrio (pegunigalsidase alfa), sponsored by Protalix BioTherapeutics, Inc. (PLX): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Elfabrio (pegunigalsidase alfa) |
| Codes | PRX-102 |
| Sponsor | Protalix BioTherapeutics, Inc. (PLX) https://sec-api.dev/companies/plx/catalysts |
| Indications | [fabry disease](https://sec-api.dev/indications/fabry-disease) |
| Modality |  |
| FDA designations | orphan, priority review |

## Timeline

### April 4, 2022: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3. Indication: Fabry disease.
- First seen 2025-03-17, last confirmed 2025-03-17.
- SEC prospectus (424B) (accession 0001104659-25-024457): "On April 4, 2022, we, together with our development and commercialization partner for PRX-102, Chiesi, announced positive topline results from our BALANCE study, a pivotal phase III clinical trial evaluating PRX-102, 1 mg/kg, administered every two weeks, compared to agalsidase beta (Fabrazyme®) for the treatment of Fabry disease." https://www.sec.gov/Archives/edgar/data/1006281/000110465925024457/tm259263d1_424b5.htm

### November 9, 2022: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2024-11-14, last confirmed 2025-11-13.
- SEC Form 10-Q (accession 0001104659-25-110824): "On November 9, 2022, we, together with Chiesi, resubmitted to the FDA a BLA for PRX-102, the name we assigned to Elfabrio internally prior to its approvals, for the potential treatment of adult patients with Fabry disease." https://www.sec.gov/Archives/edgar/data/1006281/000110465925110824/plx-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011471): "On November 9, 2022, we, together with Chiesi, resubmitted to the FDA a BLA for PRX-102, the name we assigned to Elfabrio internally prior to its approvals, for the potential treatment of adult patients with Fabry disease." https://www.sec.gov/Archives/edgar/data/1006281/000155837025011471/plx-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007063): "On November 9, 2022, we, together with Chiesi, resubmitted to the FDA a BLA for PRX-102, the name we assigned to Elfabrio internally prior to its approvals, for the potential treatment of adult patients with Fabry disease." https://www.sec.gov/Archives/edgar/data/1006281/000155837025007063/plx-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-003039): "On November 9, 2022, we, together with Chiesi, resubmitted to the FDA a BLA for PRX-102, the name we assigned to Elfabrio internally prior to its approvals, for the potential treatment of adult patients with Fabry disease." https://www.sec.gov/Archives/edgar/data/1006281/000155837025003039/plx-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-24-015612): "On November 9, 2022, we, together with Chiesi, resubmitted to the FDA a BLA for PRX-102, the name we assigned to Elfabrio internally prior to its approvals, for the potential treatment of adult patients with Fabry disease." https://www.sec.gov/Archives/edgar/data/1006281/000155837024015612/plx-20240930x10q.htm

## Same indication

- [AMT-191](https://sec-api.dev/pdufa/amt-191) (QURE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pegunigalsidase-alfa.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Elfabrio (pegunigalsidase alfa) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pegunigalsidase-alfa

```bibtex
@misc{secapidev_pdufa_pegunigalsidase_alfa_20261116,
  title        = {Elfabrio (pegunigalsidase alfa) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pegunigalsidase-alfa}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pegunigalsidase_alfa_20261116","title":"Elfabrio (pegunigalsidase alfa) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pegunigalsidase-alfa","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
